The estimated Net Worth of Gwynn Williams is at least $69.6 Million dollars as of 28 July 2003. Gwynn Williams owns over 68,700 units of Biomarin Pharmaceutical stock worth over $68,889,261 and over the last 21 years Gwynn sold BMRN stock worth over $687,000.
Gwynn has made over 1 trades of the Biomarin Pharmaceutical stock since 2003, according to the Form 4 filled with the SEC. Most recently Gwynn sold 68,700 units of BMRN stock worth $687,000 on 28 July 2003.
The largest trade Gwynn's ever made was selling 68,700 units of Biomarin Pharmaceutical stock on 28 July 2003 worth over $687,000. On average, Gwynn trades about 7,633 units every 0 days since 2003. As of 28 July 2003 Gwynn still owns at least 812,565 units of Biomarin Pharmaceutical stock.
You can see the complete history of Gwynn Williams stock trades at the bottom of the page.
Gwynn's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy und Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: